Bart L. Rottier

1.1k total citations
44 papers, 550 citations indexed

About

Bart L. Rottier is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Epidemiology. According to data from OpenAlex, Bart L. Rottier has authored 44 papers receiving a total of 550 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 14 papers in Physiology and 8 papers in Epidemiology. Recurrent topics in Bart L. Rottier's work include Cystic Fibrosis Research Advances (20 papers), Inhalation and Respiratory Drug Delivery (18 papers) and Asthma and respiratory diseases (14 papers). Bart L. Rottier is often cited by papers focused on Cystic Fibrosis Research Advances (20 papers), Inhalation and Respiratory Drug Delivery (18 papers) and Asthma and respiratory diseases (14 papers). Bart L. Rottier collaborates with scholars based in Netherlands, United States and United Kingdom. Bart L. Rottier's co-authors include Henderik W. Frijlink, Anne H. de Boer, Paul Hagedoorn, Onno W. Akkerman, Gerard H. Koppelman, Daan J. Touw, Nicole Boluyt, Bruce K. Rubin, Harry Heijerman and Steve Turner and has published in prestigious journals such as PLoS ONE, PEDIATRICS and Cochrane Database of Systematic Reviews.

In The Last Decade

Bart L. Rottier

39 papers receiving 529 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bart L. Rottier Netherlands 13 401 254 52 45 39 44 550
Louise Lannefors Sweden 10 717 1.8× 141 0.6× 74 1.4× 33 0.7× 56 1.4× 24 851
Elpis Hatziagorou Greece 13 554 1.4× 146 0.6× 85 1.6× 35 0.8× 30 0.8× 89 731
Linda Pedder Canada 8 423 1.1× 131 0.5× 59 1.1× 16 0.4× 26 0.7× 12 555
Carlos Badiola Spain 12 404 1.0× 385 1.5× 50 1.0× 42 0.9× 41 1.1× 23 626
Mateusz Bednarek Switzerland 6 377 0.9× 206 0.8× 30 0.6× 27 0.6× 48 1.2× 28 510
C. Moriarty Australia 10 756 1.9× 97 0.4× 82 1.6× 18 0.4× 34 0.9× 20 838
Siobhain Mulrennan Australia 13 328 0.8× 76 0.3× 98 1.9× 57 1.3× 44 1.1× 48 521
N. Cobos Spain 17 595 1.5× 324 1.3× 119 2.3× 14 0.3× 29 0.7× 31 811
Sunil Mehra United States 12 863 2.2× 620 2.4× 102 2.0× 16 0.4× 43 1.1× 34 1.0k
Christopher Lewis New Zealand 13 551 1.4× 172 0.7× 174 3.3× 16 0.4× 23 0.6× 30 785

Countries citing papers authored by Bart L. Rottier

Since Specialization
Citations

This map shows the geographic impact of Bart L. Rottier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart L. Rottier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart L. Rottier more than expected).

Fields of papers citing papers by Bart L. Rottier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart L. Rottier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart L. Rottier. The network helps show where Bart L. Rottier may publish in the future.

Co-authorship network of co-authors of Bart L. Rottier

This figure shows the co-authorship network connecting the top 25 collaborators of Bart L. Rottier. A scholar is included among the top collaborators of Bart L. Rottier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart L. Rottier. Bart L. Rottier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hagedoorn, Paul, Bart L. Rottier, Floris Grasmeijer, et al.. (2025). Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis. Pharmaceutics. 17(3). 347–347. 1 indexed citations
2.
Touw, Daan J., Hester van der Vaart, Arno R. Bourgonje, et al.. (2024). Evaluation of Target Attainment for Tobramycin in Children and Adults with Cystic Fibrosis. Journal of Clinical Medicine. 13(9). 2641–2641. 2 indexed citations
3.
Bannier, Michiel, Monique H. Reijers, Hester van der Vaart, et al.. (2024). Potential, Pitfalls, and Future Directions for Remote Monitoring of Chronic Respiratory Diseases: Multicenter Mixed Methods Study in Routine Cystic Fibrosis Care. Journal of Medical Internet Research. 26. e54942–e54942. 5 indexed citations
4.
Bannier, Michiel, Monique H. Reijers, Hester van der Vaart, et al.. (2024). Remote monitoring and teleconsultations can reduce greenhouse gas emissions while maintaining quality of care in cystic fibrosis. Frontiers in Digital Health. 6. 1469860–1469860.
5.
Mian, Paola, et al.. (2023). Pharmacy compounded pilocarpine: An adequate solution to overcome shortage of pilogel® discs for sweat testing in patients with cystic fibrosis. Journal of Cystic Fibrosis. 23(1). 126–131. 2 indexed citations
6.
Gaillard, Erol, Claudia E. Kuehni, Steve Turner, et al.. (2021). European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years. European Respiratory Journal. 58(5). 2004173–2004173. 133 indexed citations
7.
Koopman, Timco, Bart L. Rottier, Arja ter Elst, & Wim Timens. (2020). A case report of an unusual non-mucinous papillary variant of CPAM type 1 with KRAS mutations. BMC Pulmonary Medicine. 20(1). 52–52. 5 indexed citations
8.
Nenna, Raffaella, Katie Hunt, Theodore Dassios, et al.. (2019). Key paediatric messages from the 2018 European Respiratory Society International Congress. ERJ Open Research. 5(2). 241–2018.
9.
Rottier, Bart L., et al.. (2017). Drugs during pregnancy and breast feeding in women diagnosed with Cystic Fibrosis - An update. Journal of Cystic Fibrosis. 17(1). 17–25. 26 indexed citations
10.
Grigg, Jonathan, Ian M. Balfour‐Lynn, Mark L. Everard, et al.. (2017). Key paediatric messages from the 2016 European Respiratory Society International Congress. ERJ Open Research. 3(1). 127–2016. 2 indexed citations
11.
Roukema, Jolt, Annemie L. M. Boehmer, Marianne Brouwer, et al.. (2016). The virtual asthma clinic: Description and analysis of website-use. PA4375–PA4375. 1 indexed citations
12.
Siebelink, Marion J., et al.. (2015). Tolerance of Organ Transplant Recipients to Physical Activity during a High-Altitude Expedition: Climbing Mount Kilimanjaro. PLoS ONE. 10(11). e0142641–e0142641. 21 indexed citations
13.
Hagedoorn, Paul, et al.. (2014). Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers. PLoS ONE. 9(6). e99304–e99304. 33 indexed citations
14.
Rottier, Bart L. & Bruce K. Rubin. (2013). Asthma medication delivery: Mists and myths. Paediatric Respiratory Reviews. 14(2). 112–118. 17 indexed citations
15.
Rottier, Bart L., et al.. (2012). Jejunoileal atresia and cystic fibrosis: don’t miss it. BMC Research Notes. 5(1). 677–677. 8 indexed citations
16.
Rottier, Bart L. & Anne H. de Boer. (2010). Authors' Responses. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 23(2). 114–118. 1 indexed citations
17.
Vries, Tjalling W. de, Bart L. Rottier, Doetie Gjaltema, et al.. (2009). Comparative in vitro evaluation of four corticosteroid metered dose inhalers: Consistency of delivered dose and particle size distribution. Respiratory Medicine. 103(8). 1167–1173. 15 indexed citations
18.
Rottier, Bart L., et al.. (2009). Changes in Performance of the Pari eFlow ® Rapid and Pari LC Plus™ during 6 Months Use by CF Patients. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 22(3). 263–269. 55 indexed citations
19.
Vries, Tjalling W. de, et al.. (2008). The influence of inhaled corticosteroids and spacer devices on the growth of respiratory pathogenic microorganisms. American Journal of Infection Control. 37(3). 237–240. 5 indexed citations
20.
Duiverman, E. J., et al.. (2003). Richtlijn ' Astmabehandeling bij kinderen' van kinderlongartsen (2e herziening). II. Medicamenteuze behandeling. Data Archiving and Networked Services (DANS). 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Louise Lannefors Breakdown of academic impact, for papers by Elpis Hatziagorou Breakdown of academic impact, for papers by Linda Pedder Breakdown of academic impact, for papers by Carlos Badiola Breakdown of academic impact, for papers by Mateusz Bednarek Breakdown of academic impact, for papers by C. Moriarty Breakdown of academic impact, for papers by Siobhain Mulrennan Breakdown of academic impact, for papers by N. Cobos Breakdown of academic impact, for papers by Sunil Mehra Breakdown of academic impact, for papers by Christopher Lewis
Rankless by CCL
2026